Cite
HARVARD Citation
Tampaki, E. et al. (2018). Cabozantinib and Vandetanib in medullary thyroid carcinoma: mitochondrial function and its potential as a therapeutic target towards novel strategies to design anti-CSCs drugs. Cancer biology & therapy. 19 (10), pp. 847-849. [Online].